CVS Health (CVS)
(Delayed Data from NYSE)
$53.19 USD
-1.90 (-3.45%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $53.38 +0.19 (0.36%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.19 USD
-1.90 (-3.45%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $53.38 +0.19 (0.36%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth F Momentum C VGM
Zacks News
Teladoc (TDOC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Telehealth provider, Teladoc Inc. (TDOC ) is scheduled to report fourth-quarter and full-year 2016 results on Jan 27.
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fifth Street Asset Management, Cray, CVS Health, Mylan and Impax Laboratories highlighted as Zacks Bull and Bear of the Day
CVS Debuts Cheap EpiPen Alternative
by Madeleine Johnson
On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.
Rite Aid (RAD) Q3 Earnings Lag, Walgreens Merger on Track
by Zacks Equity Research
Rite Aid (RAD) posted dismal third-quarter fiscal 2016 results.
CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance
by Zacks Equity Research
In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)
CVS Health Revises View for 2016 & 2017, Declares Dividend
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced strategies to drive long-term growth and shareholders' value.
CVS Health Introduces Transform Diabetes Care Program
by Zacks Equity Research
CVS Health Corporation (CVS) recently unveils Transform Diabetes Care Program which will help the company's PBM clients improve health outcome of diabetic patients.
Target Soars 8% on Strong Q3 Earnings, E-Commerce Growth
by Madeleine Johnson
On Wednesday, shares of everyone's favorite store, Target Corp. (TGT), are soaring, up around 8% to $77 per share in morning trading after the company posted impressive third quarter financial results.
Company News for November 09, 2016
by Zacks Equity Research
Companies in the News are: VRX,CVS,DHI,HTZ
Stock Market News for July 28, 2016
by Zacks Equity Research
Your Next Stock Should Be Making New Highs
by Kevin Matras
This week, Kevin Matras talks about stocks making new highs and why you shouldn't be afraid to buy them. Highlighted stocks include GPK, LNDC, AIZ, CVS and GIII.